Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer

Inclusion Criteria: * Adult male \>/= 18 years of age * Patients with histologically confirmed prostate cancer * Progressive disease manifest (within 6 weeks of screening) by either * imaging modalities (bone scan, MRI or CT) OR * biochemical progression (PSA) * Performance status of 60 or higher on Karnofsky scale * Subject's schedule permits compliance with all study procedures * Ability to understand and willingness to sign a written informed consent form Exclusion Criteria: * Previous anaphylactic reaction to huJ591 antibody or FDG imaging * On any new anticancer therapy (GnRH analog allowed) while on the study * Hepatic lab values: Bilirubin\>1.5 ULN; AST/ALT \>2.5 ULN; Albumin \< 2 g/dL; GGT \> 2.5 ULN if Alkaline Phostphatase \>2.5 ULN * Renal lab values: Creatinine \> 1.5 ULN * Other severe acute or chronic medical condition that may increase the risk associated with study participation or investigational product administration